Lanreotide , as compared with placebo , was associated with significantly prolonged progression-free survival ( median not reached vs. median of 18.0 months , P < 0.001 by the stratified log-rank test ; hazard ratio for progression or death , 0.47 ; 95 % confidence interval [ CI ] , 0.30 to 0.73 ) .